Boston Scientific Announces Update on LOTUS Edge™ Aortic Valve System
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- US stocks set for lower open as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Boston Scientific (BSX) PT Lowered to $30 at Stifel Following Lotus Delay
November 29, 2017 1:42 PM ESTStifel lowered its price target on Boston Scientific (NYSE: BSX) to $30.00 (from $32.00) while maintaining a Buy rating following the company's confirmation of another Lotus EDGE (TAVR) US/EU delay.
On this mornings call, BSX reaffirmed a strong commitment to Lotus, although... More
